Zum Inhalt springen


Covid-19, Remdesivir, Gilead Science and our Fund “ACATIS Aktien Global Fonds”

Kategorie: Blog Schweiz

by Eva Maria Zaragoza Laguarda, Institutional Sales

Our global equity fund “ACTIS Aktien Global Fonds”, for quite a while now, has been paying attention to companies that have a strong position in the fight against viruses or bacteria.

In that arena, one of those companies that investors can find in the portfolio is the US Group “Gilead Science Inc”, a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

The company researches and commercializes therapies, such as for HIV, hepatitis B + C and influenza and was involved, among other projects, in the development of Roche's world-leading influenza medicine "Tamiflu". Under Gilead Science we also find Remdesivir, it was its drug candidate to fight against Ebola, it also showed to be a candidate to work against SARS and MERS. Remdesivir appears to be an effective way to treat COVID-19 symptoms, the drug is in two Phase3 clinical studies for its evaluation.



Möchten Sie von uns automatisch auf dem neuesten Stand gehalten werden?

Dann füllen Sie bitte unser Kontaktformular aus und wir werden Sie in unseren Verteiler aufnehmen.